Precision oncology firm Erasca Q3 net loss remains flat

Overview

• Erasca reports Q3 net loss of $30.6 mln, similar to last year

• R&D expenses decreased to $22.5 mln from $27.6 mln year-over-year

• Company's cash position of $362 mln expected to fund operations into H2 2028

Outlook

• Company expects initial Phase 1 data for ERAS-0015 and ERAS-4001 in 2026

• Erasca's cash reserves expected to fund operations into H2 2028

Result Drivers

• PATENT ISSUANCE - U.S. patent issued for pan-RAS molecular glue ERAS-0015, strengthening intellectual property portfolio

• LEADERSHIP PROMOTION - Robert Shoemaker, Ph.D., promoted to chief scientific officer, reinforcing scientific leadership

• R&D expenses were $22.5 million for the quarter ended September 30, 2025, compared to $27.6 million for the quarter ended September 30, 2024.

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Erasca Inc is $4.00, about 41% above its November 11 closing price of $2.36

Press Release: ID:nGNX9GvYyv

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)